XSHE
300039
Market cap807mUSD
Oct 09, Last price
5.39CNY
1D
4.26%
1Q
20.04%
Jan 2017
-31.51%
IPO
22.13%
Name
Shanghai Kaibao Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Kaibao Pharmaceutical CO.,Ltd specializes in the research, development, manufacturing, and sale of modern Traditional Chinese Medicines, primarily operating within China. Its diverse product lineup features several key pharmaceutical solutions. These include: Tanreqing injection, which is extensively utilized for addressing conditions like pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. Tanreqing capsules, formulated to reduce internal heat, detoxify the system, and clear phlegm. Tiopronin for injection, designed to enhance liver function for various acute and chronic hepatitis patients. Tiopronin enteric-coated tablets, prescribed as a supplementary therapy for managing chronic hepatitis. Xiongdan dropping pills, known for their efficacy in alleviating heat, calming the liver, and promoting improved vision. Established in 2000, the company's operations are based in Shanghai, China.
Key people
Jingwei Mu
Chairman of the Board · since 2020
Youlong Chen
Chief Financial Officer · since 2024
Yingbin Zhou
General Manager, Director · since 2023
Shaoyong Liu
Deputy General Manager, Director · since 2011
Chongbang Wang
Deputy General Manager · since 2012
Tao Zhang
Deputy General Manager · since 2020
Yingjun Zhu
Deputy General Manager
Liwang Ren
Secretary of the Board, Director · since 2024
Mingwei Feng
Director · since 2011
Shuzhong Jing
Director · since 2023
Jianzhong Liu
Deputy General Manager, Director · since 2023
Laian Mu
Director · since 2008
Guoming Wang
Director · since 2024
Dongsheng Xue
Deputy General Manager, Director · since 2011
Zhenni Li
Independent Director · since 2023
Hong Ma
Independent Director · since 2023
Zhuguang Ye
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||